Antibody-drug conjugate (ADC) development continues to evolve, with increased molecular complexity leading to new opportunities and challenges across design, development, and manufacturing. The industry is advancing novel technologies to support...
Join Viralgen, Genosafe and DarkHorse Consulting as they discuss their experience with novel capsid manufacturing, analytical testing and regulatory guidance. Key learning objectives: - Ways to address the complexity of...
This webinar shows how a system-based primary packaging approach—like the West Synchrony™ prefillable syringe system—can streamline tech transfer, simplify GMP qualification, and reduce complexity, cost, and timelines for injectable drug...
The webinar also highlights the growing role of AI within regulated manufacturing environments. Rather than treating AI as an add-on, the session outlines how to embed it into validated frameworks...
This webinar series explores two powerful, complementary disciplines that CDMOs leverage to tackle these challenges head-on. First, we examine the solid-state domain, exploring how targeted crystallization development can directly address...
CHO expression continues to evolve, and recent advances are reshaping how quickly and efficiently high-performing cell lines are developed. In this webinar, experts explore the latest innovations in the GS®...
Bringing innovative antibody therapeutics to market quickly requires more than upstream efficiency. It demands adaptable and robust downstream purification strategies. As novel mAb formats increase in complexity, purification challenges grow....
Immune checkpoint inhibitors have transformed cancer treatment, but response rates remain limited, and immune-related toxicities continue to pose challenges. Gene editing of therapeutic T cells offers a promising path to...
Technology transfer to a CDMO is rarely as simple as handing over a data package. From documentation gaps and equipment differences to method variability and global standards, many programs encounter...
In this webinar, Lonza experts share insights from 70+ bispecific programs, revealing the most common early‑stage risks across analytical development, downstream purification, and drug product formulation. You’ll learn where challenges...
